The article discusses the role of nivolumab plus with combination of Ipilimumab to improves survival in patients with metastatic non-small cell lung cancer (NSCLC). It mentions that results of the final analysis of part 1 of CheckMate 227 were presented at the ESMO Congress 2019 and published online simultaneously.